{"id":186988,"date":"2026-08-07T12:45:01","date_gmt":"2026-08-07T07:15:01","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=186988"},"modified":"2026-08-07T12:45:03","modified_gmt":"2026-08-07T07:15:03","slug":"onesource-specialty-pharma-share-price-target-2027-2028-2030","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/","title":{"rendered":"Onesource Specialty Pharma Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>CMP Rs 1640. FY26 EPS Rs N\/A; approximately 12% annual growth. Target 2027: Rs 1,945 (+19%). Target 2028: Rs 2,530. Target 2030: Rs 4,280 (+161%).<\/em><\/p>\n<p>Onesource Specialty Pharma at Rs 1,640 is positioned as India&#8217;s only dedicated CDMO for GLP-1 class drug-device combinations, specifically manufacturing injectable pens for semaglutide-type weight-loss drugs. In the global obesity treatment wave, CDMO capacity for GLP-1 injectables is among the most scarce manufacturing capabilities globally. The Onesource share price target of Rs 1,945 for 2027, rising to Rs 4,280 by 2030, reflects 30 percent annual earnings growth from a still loss-making base.<\/p>\n<p>The Onesource Specialty Pharma share price target of Rs 1,945 for 2027, rising to Rs 4,280 by 2030, reflects approximately 12% annual earnings growth with a forward multiple consistent with CDMO (GLP-1 Injectables) peers. This article covers the Onesource Specialty Pharma share price target 2027, 2028, and 2030 based on FY26 financials and analyst estimates as of August 2026.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=onesource-specialty-pharma-tgt\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Onesource_Specialty_Pharma_Company_Overview\" title=\"Onesource Specialty Pharma Company Overview\">Onesource Specialty Pharma Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Why_Is_the_Onesource_Specialty_Pharma_Share_Price_Target_Set_at_Rs_1945_for_2027\" title=\"Why Is the Onesource Specialty Pharma Share Price Target Set at Rs 1,945 for 2027\">Why Is the Onesource Specialty Pharma Share Price Target Set at Rs 1,945 for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#GLP-1_Injectable_Pen_CDMO_Capacity_Is_Among_the_Scarcest_in_Global_Pharma\" title=\"GLP-1 Injectable Pen CDMO Capacity Is Among the Scarcest in Global Pharma\">GLP-1 Injectable Pen CDMO Capacity Is Among the Scarcest in Global Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Semaglutide_Class_Drug_Demand_Creates_Multi-Year_Manufacturing_Revenue_Backlog\" title=\"Semaglutide Class Drug Demand Creates Multi-Year Manufacturing Revenue Backlog\">Semaglutide Class Drug Demand Creates Multi-Year Manufacturing Revenue Backlog<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Drug-Device_Combination_Manufacturing_Expertise_Has_a_Very_High_Entry_Barrier\" title=\"Drug-Device Combination Manufacturing Expertise Has a Very High Entry Barrier\">Drug-Device Combination Manufacturing Expertise Has a Very High Entry Barrier<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Strides_and_Steriscience_Ecosystem_Provides_Regulatory_and_Technical_Backbone\" title=\"Strides and Steriscience Ecosystem Provides Regulatory and Technical Backbone\">Strides and Steriscience Ecosystem Provides Regulatory and Technical Backbone<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Path_to_Profitability_by_FY28_Is_the_Key_Milestone_for_Target_Achievement\" title=\"Path to Profitability by FY28 Is the Key Milestone for Target Achievement\">Path to Profitability by FY28 Is the Key Milestone for Target Achievement<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Onesource_Specialty_Pharma_Share_Price_Targets_2027_2028_and_2030\" title=\"Onesource Specialty Pharma Share Price Targets 2027, 2028 and 2030\">Onesource Specialty Pharma Share Price Targets 2027, 2028 and 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Onesource_Specialty_Pharma_Share_Price_Target_2027_Rs_1945\" title=\"Onesource Specialty Pharma Share Price Target 2027: Rs 1,945\">Onesource Specialty Pharma Share Price Target 2027: Rs 1,945<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Onesource_Specialty_Pharma_Share_Price_Target_2028_Rs_2530\" title=\"Onesource Specialty Pharma Share Price Target 2028: Rs 2,530\">Onesource Specialty Pharma Share Price Target 2028: Rs 2,530<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Onesource_Specialty_Pharma_Share_Price_Target_2030_Rs_4280\" title=\"Onesource Specialty Pharma Share Price Target 2030: Rs 4,280\">Onesource Specialty Pharma Share Price Target 2030: Rs 4,280<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Bull_Case_and_Bear_Case_for_the_Onesource_Specialty_Pharma_Share_Price_Target_2030\" title=\"Bull Case and Bear Case for the Onesource Specialty Pharma Share Price Target 2030\">Bull Case and Bear Case for the Onesource Specialty Pharma Share Price Target 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Bull_Case_Rs_5478\" title=\"Bull Case: Rs 5,478\">Bull Case: Rs 5,478<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Bear_Case_Rs_3253\" title=\"Bear Case: Rs 3,253\">Bear Case: Rs 3,253<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Key_Risks_to_the_Onesource_Specialty_Pharma_Share_Price_Target\" title=\"Key Risks to the Onesource Specialty Pharma Share Price Target\">Key Risks to the Onesource Specialty Pharma Share Price Target<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#USFDA_Inspection_and_Compliance_Risk\" title=\"USFDA Inspection and Compliance Risk\">USFDA Inspection and Compliance Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Currency_Risk_on_Export_Revenue\" title=\"Currency Risk on Export Revenue\">Currency Risk on Export Revenue<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Pricing_Pressure_in_Regulated_Generic_Markets\" title=\"Pricing Pressure in Regulated Generic Markets\">Pricing Pressure in Regulated Generic Markets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Clinical_Trial_and_Pipeline_Risk\" title=\"Clinical Trial and Pipeline Risk\">Clinical Trial and Pipeline Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#How_to_Invest_in_Onesource_Specialty_Pharma\" title=\"How to Invest in Onesource Specialty Pharma\">How to Invest in Onesource Specialty Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Frequently_Asked_Questions_on_Onesource_Specialty_Pharma_Share_Price_Target_2027_2028_and_2030\" title=\"Frequently Asked Questions on Onesource Specialty Pharma Share Price Target 2027 2028 and 2030\">Frequently Asked Questions on Onesource Specialty Pharma Share Price Target 2027 2028 and 2030<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#What_is_the_Onesource_Specialty_Pharma_share_price_target_for_2027\" title=\"What is the Onesource Specialty Pharma share price target for 2027?\">What is the Onesource Specialty Pharma share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#What_is_the_Onesource_Specialty_Pharma_share_price_target_for_2030\" title=\"What is the Onesource Specialty Pharma share price target for 2030?\">What is the Onesource Specialty Pharma share price target for 2030?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#Is_Onesource_Specialty_Pharma_a_good_long-term_investment\" title=\"Is Onesource Specialty Pharma a good long-term investment?\">Is Onesource Specialty Pharma a good long-term investment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#What_do_most_investors_miss_about_Onesource_Specialty_Pharma\" title=\"What do most investors miss about Onesource Specialty Pharma?\">What do most investors miss about Onesource Specialty Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#What_is_the_bull_case_for_the_Onesource_Specialty_Pharma_share_price_target_2030\" title=\"What is the bull case for the Onesource Specialty Pharma share price target 2030?\">What is the bull case for the Onesource Specialty Pharma share price target 2030?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#What_are_the_main_risks_to_the_Onesource_Specialty_Pharma_share_price_target\" title=\"What are the main risks to the Onesource Specialty Pharma share price target?\">What are the main risks to the Onesource Specialty Pharma share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#What_is_Onesource_Specialty_Pharmas_52-week_high_and_low_share_price\" title=\"What is Onesource Specialty Pharma&#8217;s 52-week high and low share price?\">What is Onesource Specialty Pharma&#8217;s 52-week high and low share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/onesource-specialty-pharma-share-price-target-2027-2028-2030\/#How_can_I_buy_Onesource_Specialty_Pharma_shares\" title=\"How can I buy Onesource Specialty Pharma shares?\">How can I buy Onesource Specialty Pharma shares?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Onesource_Specialty_Pharma_Company_Overview\"><\/span><strong>Onesource Specialty Pharma Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\">\n<tbody>\n<tr style=\"background: #1F4E79; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Metric<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Details<\/th>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">NSE Ticker<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\"><a href=\"https:\/\/univest.in\/user\/stocks\/onesource\/onesource-specl-pharma-l-share-price-today\">ONESOURCE<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Sector<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">CDMO (GLP-1 Injectables)<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">CMP (05 Aug 2026)<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 1640<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">52-Week High<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 2,100<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">52-Week Low<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 1,200<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Market Cap<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 18,653 Cr<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">FY26 EPS<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">See rationale<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Promoter Holding<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">54%<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">12M Consensus<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">\u20b91,947 (+19%)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Onesource Specialty Pharma Share Price Target 2027<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 1,945 (+19%)<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Onesource Specialty Pharma Share Price Target 2028<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 2,530 (+54%)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Onesource Specialty Pharma Share Price Target 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 4,280 (+161%)<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bull Case 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 5,478<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bear Case 2030<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 3,253<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"border-left: 4px solid #e67e22; background: #FEF9F0; padding: 10px 16px;\"><strong>What most investors miss:<\/strong> Carved out of the Strides and Steriscience ecosystem, Onesource is positioned as a picks-and-shovels GLP-1 play, a CDMO manufacturer of injectable pens and drug-device combinations for semaglutide-class weight-loss drugs. This is a scarce, high-margin capability riding the obesity drug boom. The company is still loss-making, and the 2027 target is anchored to the street consensus, not EPS multiples. The scale-up to profitability through FY28 to FY29 is the critical milestone.<\/p>\n<p>Since the company is still loss-making, we&#8217;ve anchored to the \u20b91,947 street target and rolled it forward assuming approximately30% underlying growth. . The share price targets of Rs 1,945 for 2027, Rs 2,530 for 2028, and Rs 4,280 for 2030 are derived from this earnings trajectory and peer multiples.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_the_Onesource_Specialty_Pharma_Share_Price_Target_Set_at_Rs_1945_for_2027\"><\/span><strong>Why Is the Onesource Specialty Pharma Share Price Target Set at Rs 1,945 for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"GLP-1_Injectable_Pen_CDMO_Capacity_Is_Among_the_Scarcest_in_Global_Pharma\"><\/span><strong>GLP-1 Injectable Pen CDMO Capacity Is Among the Scarcest in Global Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the foundational driver of the Onesource Specialty Pharma share price target of Rs 1,945 for 2027 and Rs 4,280 by 2030. Since the company is still loss-making, we&#8217;ve anchored to the \u20b91,947 street target and rolled it forward assuming approximately30% underlying growth. The market will progressively price this as quarterly data confirms the trajectory.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Semaglutide_Class_Drug_Demand_Creates_Multi-Year_Manufacturing_Revenue_Backlog\"><\/span><strong>Semaglutide Class Drug Demand Creates Multi-Year Manufacturing Revenue Backlog<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Investors analysing the Onesource Specialty Pharma share price target should track this dimension quarterly, as it provides the clearest signal of whether the compounding thesis is on track. Evidence of sustained improvement in this area is the primary re-rating catalyst for the Onesource Specialty Pharma share price target 2028 of Rs 2115.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Drug-Device_Combination_Manufacturing_Expertise_Has_a_Very_High_Entry_Barrier\"><\/span><strong>Drug-Device Combination Manufacturing Expertise Has a Very High Entry Barrier<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This structural factor is often underweighted in standard Onesource Specialty Pharma share price target analyses, which focus on trailing earnings multiples rather than the competitive positioning embedded in the long-term franchise value. Its persistence through economic cycles is what differentiates the Onesource Specialty Pharma share price target 2030 case from a short-term trading call.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Strides_and_Steriscience_Ecosystem_Provides_Regulatory_and_Technical_Backbone\"><\/span><strong>Strides and Steriscience Ecosystem Provides Regulatory and Technical Backbone<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>For the Onesource Specialty Pharma share price target of Rs 4,280 to materialise by 2030, this factor needs to remain intact and compound over 4 years. Quarterly updates on this metric provide the earliest warning signal of any deviation from the Onesource Specialty Pharma share price target base case assumptions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Path_to_Profitability_by_FY28_Is_the_Key_Milestone_for_Target_Achievement\"><\/span><strong>Path to Profitability by FY28 Is the Key Milestone for Target Achievement<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As India&#8217;s economy compounds through 2027 to 2030, this factor provides an additional secular tailwind that is layered on top of the Onesource Specialty Pharma-specific earnings growth already embedded in the Rs 1,945 target for 2027 and the Rs 4,280 target for 2030.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Onesource_Specialty_Pharma_Share_Price_Targets_2027_2028_and_2030\"><\/span><strong>Onesource Specialty Pharma Share Price Targets 2027, 2028 and 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Onesource_Specialty_Pharma_Share_Price_Target_2027_Rs_1945\"><\/span><strong>Onesource Specialty Pharma Share Price Target 2027: Rs 1,945<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Onesource Specialty Pharma share price target 2027 is Rs 1,945, representing approximately 19 percent upside from CMP Rs 1640. Since the company is still loss-making, we&#8217;ve anchored to the \u20b91,947 street target and rolled it forward assuming approximately30% underlying growth.. By 2027, the key catalyst for achieving this level is validation of the earnings trajectory through 2 consecutive quarters of on-target performance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Onesource_Specialty_Pharma_Share_Price_Target_2028_Rs_2530\"><\/span><strong>Onesource Specialty Pharma Share Price Target 2028: Rs 2,530<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Onesource Specialty Pharma share price target 2028 is Rs 2,530, implying approximately 54 percent upside from CMP. By 2028, Onesource Specialty Pharma should have demonstrated through a full earnings cycle that the approximately 12% growth assumption is sustainable, supporting a re-rating toward the Onesource Specialty Pharma share price target 2028 level at a forward multiple consistent with sector peers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Onesource_Specialty_Pharma_Share_Price_Target_2030_Rs_4280\"><\/span><strong>Onesource Specialty Pharma Share Price Target 2030: Rs 4,280<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Onesource Specialty Pharma share price target 2030 is Rs 4,280, implying approximately 161 percent upside from CMP and a 4-year CAGR of approximately 27% from current levels. By 2030, Onesource Specialty Pharma should be a mature, well-understood franchise with a track record of consistent compounding that justifies the target multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_for_the_Onesource_Specialty_Pharma_Share_Price_Target_2030\"><\/span><strong>Bull Case and Bear Case for the Onesource Specialty Pharma Share Price Target 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_5478\"><\/span><strong>Bull Case: Rs 5,478<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bull case Onesource Specialty Pharma share price target of Rs 5,478 by 2030: Rs 5,500 by 2030, if GLP-1 demand exceeds global supply and Onesource secures multi-year contracts with multiple top-tier pharma companies, driving 40 percent annual revenue growth and early profitability by FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_Rs_3253\"><\/span><strong>Bear Case: Rs 3,253<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The bear case Onesource Specialty Pharma share price target of Rs 3,253 by 2030: Rs 2,800 by 2030, if GLP-1 drug demand growth is slower than expected, global pharma companies prefer in-house manufacturing, and Onesource&#8217;s losses persist beyond FY28, requiring dilutive equity raises.<\/p>\n<table style=\"border-collapse: collapse; width: 100%; margin: 16px 0;\">\n<tbody>\n<tr style=\"background: #1F4E79; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Scenario<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Target by 2030<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Return<\/th>\n<th style=\"padding: 8px 12px; text-align: left; border: 1px solid #ddd;\">Key Assumption<\/th>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bull Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 5,478<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+234%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Upside scenario with favourable execution and sector conditions<\/td>\n<\/tr>\n<tr style=\"background: #f5f5f5;\">\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Base Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 4,280<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+161%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">approximately 12% EPS CAGR; peer-multiple sustained through FY31<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Bear Case<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Rs 3,253<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">+98%<\/td>\n<td style=\"padding: 8px 12px; border: 1px solid #ddd;\">Downside scenario with adverse execution or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Onesource_Specialty_Pharma_Share_Price_Target\"><\/span><strong>Key Risks to the Onesource Specialty Pharma Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"USFDA_Inspection_and_Compliance_Risk\"><\/span><strong>USFDA Inspection and Compliance Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Any USFDA warning letter or import alert on Onesource Specialty Pharma&#8217;s manufacturing facilities would delay product launches and revenue recognition, directly reducing the earnings trajectory behind the Onesource Specialty Pharma share price target. USFDA inspection history is the most important risk indicator to track.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Currency_Risk_on_Export_Revenue\"><\/span><strong>Currency Risk on Export Revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Onesource Specialty Pharma&#8217;s international revenue is primarily in US dollars and euros. Any significant INR appreciation against these currencies would reduce the INR value of reported revenues and EPS, compressing the Onesource Specialty Pharma share price target earnings assumptions.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Pricing_Pressure_in_Regulated_Generic_Markets\"><\/span><strong>Pricing Pressure in Regulated Generic Markets<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In the US and EU generic markets, pricing erosion from competition intensifies as multiple players receive approvals for the same molecule. Any acceleration in generic pricing erosion in Onesource Specialty Pharma&#8217;s key export products would compress the Onesource Specialty Pharma share price target revenue base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Clinical_Trial_and_Pipeline_Risk\"><\/span><strong>Clinical Trial and Pipeline Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Any setback in Onesource Specialty Pharma&#8217;s clinical trial results or regulatory approvals for pipeline products would delay the revenue ramp from specialty or novel products embedded in the Onesource Specialty Pharma share price target 2028 and 2030 assumptions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Onesource_Specialty_Pharma\"><\/span><strong>How to Invest in Onesource Specialty Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Use the Univest Screener to track Onesource Specialty Pharma&#8217;s key financial metrics including EPS growth, margin trends, and analyst upgrades or downgrades in real time. To purchase shares, open a demat account with any SEBI-registered broker and search for NSE ticker ONESOURCE. Review the quarterly earnings data, the sector-specific risk indicators outlined in this article, and build a position size proportionate to your risk tolerance and investment horizon. Monitor each quarter for the key variables most likely to move the Onesource Specialty Pharma share price target. Consult a SEBI-registered financial advisor before making any investment decision.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Use the Univest Screener to Track This Stock Live<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Onesource Specialty Pharma share price target of Rs 1,945 for 2027, Rs 2,530 for 2028, and Rs 4,280 for 2030 reflects approximately 12% annual earnings compounding and a forward multiple consistent with CDMO (GLP-1 Injectables) peers. The key drivers and risks are outlined above. Carved out of the Strides and Steriscience ecosystem, Onesource is positioned as a picks-and-shovels GLP-1 play, a CDMO manufacturer of injectable pen. For investors with a 3 to 4 year horizon and a tolerance for CDMO (GLP-1 Injectables)-specific risk, the current CMP of Rs 1640 offers a starting point for building a position aligned to the Onesource Specialty Pharma share price target 2030 thesis. Always verify data at NSE and BSE before investing.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Onesource Specialty Pharma share price live and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Onesource_Specialty_Pharma_Share_Price_Target_2027_2028_and_2030\"><\/span><strong>Frequently Asked Questions on Onesource Specialty Pharma Share Price Target 2027 2028 and 2030<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Onesource_Specialty_Pharma_share_price_target_for_2027\"><\/span><strong>What is the Onesource Specialty Pharma share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Onesource Specialty Pharma share price target for 2027 is Rs 1,945, representing approximately 19 percent upside from CMP Rs 1640 as of August 2026. Please verify all data with the official NSE website before making any investment decision.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Onesource_Specialty_Pharma_share_price_target_for_2030\"><\/span><strong>What is the Onesource Specialty Pharma share price target for 2030?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Onesource Specialty Pharma share price target for 2030 is Rs 4,280, implying approximately 161 percent upside from CMP Rs 1640. This is based on analyst estimates and is not a guaranteed return. Always verify current data at NSE India before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Onesource_Specialty_Pharma_a_good_long-term_investment\"><\/span><strong>Is Onesource Specialty Pharma a good long-term investment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Onesource Specialty Pharma has a defined analyst consensus that projects earnings compounding through FY31 based on sector-specific growth drivers outlined in this article. Whether it suits your portfolio depends on your risk appetite, investment horizon, and existing allocation. Consult a SEBI-registered financial advisor for personalised guidance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_do_most_investors_miss_about_Onesource_Specialty_Pharma\"><\/span><strong>What do most investors miss about Onesource Specialty Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Carved out of the Strides\/Steriscience ecosystem, it is positioned as a &#8216;picks-and-shovels&#8217; GLP-1 play &#8211; a contract maker of injectable pens\/drug-device combinations for semaglutide-class weight-loss drugs as patents expire &#8211; which is why the market pays up despite a TTM loss; borrowings nearly doub<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_bull_case_for_the_Onesource_Specialty_Pharma_share_price_target_2030\"><\/span><strong>What is the bull case for the Onesource Specialty Pharma share price target 2030?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case Onesource Specialty Pharma share price target for 2030 is Rs 5,478. This requires better-than-base-case execution on the key growth drivers specific to Onesource Specialty Pharma&#8217;s sector, as described in this article. These are analyst projections, not guaranteed returns.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Onesource_Specialty_Pharma_share_price_target\"><\/span><strong>What are the main risks to the Onesource Specialty Pharma share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The key risks to the Onesource Specialty Pharma share price target include sector-specific headwinds such as credit cycles (for financial companies), regulatory changes, competitive pressure, and macroeconomic slowdown. Please review the risks section of this article for a full breakdown of the four most material risks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Onesource_Specialty_Pharmas_52-week_high_and_low_share_price\"><\/span><strong>What is Onesource Specialty Pharma&#8217;s 52-week high and low share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of August 2026, Onesource Specialty Pharma&#8217;s 52-week high is approximately Rs 2,100 and the 52-week low is approximately Rs 1,200. The CMP of Rs 1640 sits between these levels. Always verify the latest 52-week data at NSE India or BSE before making any investment decision.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_can_I_buy_Onesource_Specialty_Pharma_shares\"><\/span><strong>How can I buy Onesource Specialty Pharma shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> You can buy Onesource Specialty Pharma shares through any SEBI-registered broker by searching for the NSE ticker ONESOURCE. Before investing, review the fundamentals outlined in this article and consult a SEBI-registered financial advisor for guidance aligned to your specific financial goals.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Onesource Specialty Pharma share price target 2027 is Rs 1,945 (+19%), 2028 is Rs 2,530, and 2030 is Rs 4,280 (+161%). CDMO (GLP-1 Injectables) stock. Full long<\/p>\n","protected":false},"author":35,"featured_media":186987,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-186988","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["186987"],"_edit_lock":["1786086906:29"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["79"],"rank_math_title":["Onesource Specialty Pharma Share Price Target 2027 2028 and 2030"],"rank_math_description":["Onesource Specialty Pharma share price target 2027 is Rs 1,945 (+19%), 2028 is Rs 2,530, and 2030 is Rs 4,280 (+161%). CDMO (GLP-1 Injectables) stock. Full long"],"rank_math_focus_keyword":["Onesource Specialty Pharma share price target"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_edit_last":["29"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["34957"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/onesource-specialty-pharma-share-price-target-2027-2028-2030.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/186988","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=186988"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/186988\/revisions"}],"predecessor-version":[{"id":190671,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/186988\/revisions\/190671"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/186987"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=186988"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=186988"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=186988"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}